Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Compass Score
Key Numbers
Market Cap
$42B
P/E
30
Revenue Growth
+8.0%
Gross Margin
N/A
ROE
N/A
About Edwards Lifesciences
Edwards Lifesciences is a mid-cap healthcare company listed on the NYSE, positioned as a pure-play investment vehicle for the biotech and genomics megatrend. Structural heart disease innovator with transcatheter aortic valve replacement technology. Valued at 30x trailing earnings with a $42B market capitalization, Edwards Lifesciences has delivered modest revenue growth with revenue moving +8% over the past year.
Expert Coverage
Unlock Full EW Analysis
Expert analysis and coverage for Edwards Lifesciences
Or unlock everything now with Compass, $9/moPrice & Technical Analysis
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
More in Biotech & Genomics
Eli Lilly and Company
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
DexCom Inc.
Continuous glucose monitoring leader expanding beyond diabetes management.
Recursion Pharmaceuticals
AI-driven drug discovery platform using machine learning to decode biology at scale.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.